Special Issue "Immune-Mediated and Allergic Skin Diseases: Clinical Diagnosis and Treatment"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 31 July 2020.

Special Issue Editor

Prof. Angelo Valerio Marzano
Website
Guest Editor
Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
Interests: cutaneous immunopathology; autoinflammation; neutrophilic dermatoses; chronic spontaneous urticaria; autoimmune bullous diseases; lupus erythematosus; drug-induced skin reactions

Special Issue Information

Dear Colleagues,

The skin is a site commonly involved in pathological immune responses that can take place in the epidermal and/or dermal compartments. These immunopathological reactions often occur towards self-antigens and may be due to T cell-dependent and/or autoantibody-dependent mechanisms. In many inflammatory diseases, signals of the innate immune system typically initiate skin immune responses, while cells and cytokines of the adaptive immune system perpetuate the inflammation. An extensive crosstalk between the different cell types of the immune system, tissue cells, and pathogens is responsible for the complexity of skin immune reactions.

The recent increase in the understanding of immune-mediated and allergic skin disease pathogenesis has been enormous, leading to the development and introduction of new targeted therapeutic regimens. Moreover, identifying both clinical phenotypes and possible trajectories of treatment outcome has allowed for the most selective management to be applied to each patient. Hopefully, the near future will see a genetic and pathogenesis-driven treatment of those diseases.

This Special Issue aims to bring together the most relevant scientific research on immune-mediated and allergic skin diseases, focusing on clinical diagnosis, pathophysiology, and recent advancements in therapy.

Prof. Angelo Valerio Marzano
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immune-mediated skin diseases
  • psoriasis
  • urticaria
  • vasculitis
  • atopic dermatitis
  • connective tissue diseases
  • neutrophilic dermatoses
  • drug-induced skin reactions
  • autoinflammatory diseases
  • autoimmune bullous diseases

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience
J. Clin. Med. 2020, 9(3), 791; https://doi.org/10.3390/jcm9030791 - 13 Mar 2020
Cited by 1
Abstract
Dupilumab is an anti-interleukin-4 receptor monoclonal antibody that was recently approved for the treatment of atopic dermatitis (AD). In this single-center retrospective study, clinical baseline data of 117 severe AD patients treated with dupilumab were collected. At baseline and at weeks 4 and [...] Read more.
Dupilumab is an anti-interleukin-4 receptor monoclonal antibody that was recently approved for the treatment of atopic dermatitis (AD). In this single-center retrospective study, clinical baseline data of 117 severe AD patients treated with dupilumab were collected. At baseline and at weeks 4 and 16, disease severity was assessed through the Eczema Area and Severity Index (EASI) and quality of life through the Dermatology Life Quality Index (DLQI) questionnaire, Patient-Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), Peak Pruritus Numerical Rating Scale (NRS-itch), and VAS-sleep. Response to dupilumab was defined as an improvement of ≥75% in EASI from baseline (EASI75). At multivariate analysis, AD onset before 18 years [OR, 2.9; 95% CI, 1.2–7.2; p = 0.0207] and absence of hypereosinophilia [OR, 2.24; 95% CI, 1.03–4.86; p = 0.0412] were identified as significant predictive parameters for response to dupilumab in terms of EASI75 at week 4 but not at week 16. Significant reductions in EASI, DLQI, POEM, HADS, NRS-itch, and VAS-sleep were found between week 4 versus baseline (p < 0.0001 for all) and week 16 versus baseline (p < 0.0001 for all). Early AD onset and absence of hypereosinophilia may be suggested as predictive markers of early response to dupilumab. We confirmed the efficacy and safety of this agent along with the improvement of life quality in severe AD patients. Full article
Back to TopTop